[1]Fan N, Huang X, Chen Z, et al. Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. Sci Rep, 2018, 8(1):3317-3317. [2]Zhang Y, Xu T, Pan Z, et al. Shikonin inhibits myeloid differentiation protein-2 to prevent lipopolysaccharide-induced acute lung injury. Br J Pharmacol, 2018, 175(5):840-854. [3]Wu H, Xie J, Pan Q, et al. Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. Plos One, 2013, 8(1):e52706. [4]Lin KH, Huang MY, Cheng WC, et al. RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment. Sci Rep, 2018, 8(1):2672-2672. [5]Hsieh YS, Liao CH, Chen WS, et al. Shikonin inhibited migration and invasion of human lung cancer cells via suppression of c-Met-1mediated epithelial-to-mesenchymal transition. J Cell Biochem, 2017, 118(12):4639-4651. [6]Zhang Z, Zhang Z, Li Q, et al. Shikonin induces necroptosis by reactive oxygen species activation in nasopharyngeal carcinoma cell line CNE-2Z.J Bioenerg Biomembr, 2017, 49(3):265-272. [7]Dan L, Qian J, Wei L, et al. β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling. Oncol Lett, 2015, 10(6):3434-3442. [8]Liang W, Cui J, Zhang K, et al. Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer. Oncotarget, 2017, 8(65):109094-109106. [9]Tang JC, Zhao J, Long F, et al. Efficacy of shikonin against esophageal cancer cells and its possible mechanisms in vitro and in vivo. J Cancer, 2018, 9(1):32-40. [10]Zhai T, Hei Z, Ma Q, et al. Shikonin induces apoptosis andG0/G1 phase arrest of gallbladder cancer cells via the JNK signaling pathway. Oncol Rep, 2017, 38(6):3473-3480. [11]Yang Q, Li S, Fu Z, et al. Shikonin promotes adriamycin-induced apoptosis by upregulating caspase-3 and caspase-8 in osteosarcoma. Mol Med Rep, 2017, 16(2):1347-1352. [12]Jin SJ, Yun Y, Lei M, et al. In vivoandin vitroinduction of the apoptotic effects of oxysophoridine on colorectal cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway. Oncol Lett, 2017, 14(6):8000-8006. [13]Saeedi Borujeni MJ, Hami J, Haghir H, et al. Evaluation of Bax and Bcl-2 proteins expression in the rat hippocampus due to childhood febrile seizure. Iran J Child Neurol, 2016, 10(1):53-60. [14]Galluzzi L, Baehrecke EH, Ballabio A, et al. Molecular definitions of autophagy and related processes. Embo J, 2017, 36(13):1811-1836. [15]Maiese K. Moving to therhythm with clock (Circadian) genes, autophagy, mTOR, and SIRT1 in degenerative disease and cancer. Curr Neurovasc Res, 2017, 14(3):299-304. [16]Du X, Liu B, Luan X, et al. miR-30 decreasesmultidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med, 2018, 15(1):599-605. [17]Tao R, Sun WY, Yu DH, et al. Sodium cantharidinate induces HepG2 cell apoptosis through LC3 autophagy pathway. Oncol Rep, 2017, 38(2):1233-1239. [18]Desirée B, Katiuscia D, Pierangelo T, et al. Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. Transl Res, 2018, 193:54-71. [19]Lin QY, Wang YF, Chen DJ, et al. Cisplatin regulates cell autophagy in endometrial cancer cells via the PI3K/AKT/mTOR signalling pathway. Oncol Lett, 2017, 13(5):3567-3571. [20]欧志涛,詹远京,郭家伟,等.CIAPIN1对HepG2细胞增殖和细胞周期的影响 .实用肝脏病杂志,2018,21(1):38-41. |